Clinical Trial Update: Allogeneic Bone Marrow Transplantation for the Treatment of Genetic Disorders of Erythropoiesis [Phase 2]

View source ↗

Summary

Phase 2 trial of allogeneic bone marrow transplantation for genetic disorders of erythropoiesis, including sickle cell disease, has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Genetic Disorders, Sickle Cell Anemia | Phase 2 | Status: COMPLETED